Searchable abstracts of presentations at key conferences on calcified tissues
Volume 1 | ECTS2013 | Next issue

European Calcified Tissue Society Congress 2013

Lisbon, Portugal
18 May 2013 - 22 May 2013

Card image cap
European Calcified Tissue Society Congress 2013, 18 - 22 May 2013; Lisbon, Portugal

Oral Communications

Treatment of osteoporosis

ba0001oc5.1 | Treatment of osteoporosis | ECTS2013

A Three-year randomized sham-controlled trial of low magnitude mechanical stimulation in an elderly sample: the ‘VIBES' trial

Kiel Douglas , Hannan Marian , Sisson Emily , Bouxsein Mary , Barton Bruce , Dewkett Dawn , Magaziner Jay , Zimmerman Sheryl , Shane Elizabeth , Leary Elizabeth Teng , Carroll Danette , Allaire Brett , Lang Thomas , Rubin Clinton

Non-pharmacologic approaches to preserve or increase BMD include whole body vibration (WBV). A meta-analysis and one-year randomized trial concluded that WBV has no effect on BMD in older women; however, previous trials were relatively brief and did not include a sham control group. Therefore, we conducted the Vibration to Improve Bone in Elderly Subjects (‘VIBES’) trial, a randomized, sham-controlled trial of 10 min of daily WBV (0.3 g at 30 Hz) in seniors recruited...

ba0001oc5.2 | Treatment of osteoporosis | ECTS2013

Fracture risk factors during treatment with denosumab

Cummings Steven , Feng Amy , Black Dennis , Wagman Rachel , Austin Matt , Wang Andrea , Walimbe Mona , Wu Lucy , Lui Lily , Vittinghoff Eric

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patient’s risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...

ba0001oc5.3 | Treatment of osteoporosis | ECTS2013

Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density

Benson Charles , Robins Deborah , Recker Robert , Alam Jahangir , Chiang Alan Y , Mitlak Bruce , Sipos Adrien , Hu Leijun

Introduction: Administration of antibodies that neutralize sclerostin has been demonstrated to increase bone mass. We report the key findings of a Phase 2 study of the human sclerostin antibody, blosozumab (bmab).Methods: Study GSDB was a randomized, parallel-design, double-blind placebo-controlled study, designed to assess the dose–response relationship of bmab in postmenopausal women with low bone mineral density (BMD; lumbar spine (LS) T...

ba0001oc5.4 | Treatment of osteoporosis | ECTS2013

Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis

Graeff C , Campbell G , Pena J , Padhi D , Grossman A , Chang S , Libanati C , Gluer C-C

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...

ba0001oc5.5 | Treatment of osteoporosis | ECTS2013

Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis

Hattersley Gary , Bilezikian John , Guerriero Jonathan , Kumar Prasanna , Zanchetta Jose , Lyttle C Richard , O'Dea Louis Saint L

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

ba0001oc5.6 | Treatment of osteoporosis | ECTS2013

Testosterone replacement has a substantial benefit on bone mass, fracture incidence, libido, and sexual activities in male cardiac transplant patients: a 5-year randomized prospective controlled trial

Wagner Doris , Prenner Guenther , Dobnig Harald , Dimai Hans Peter , Pieber Thomas , Pilz Stefan , Tomaschitz Andreas , Amrein Karin , Fahrleitner-Pammer Astrid

Hypogonadism is common in cardiac transplant (CTX) patients and exerts negative effects on bone but also on libido and quality of life.We investigated whether testosterone replacement therapy (TRT) has any positive effects on bone mass, fracture incidence, and quality of sex life when administered in addition to ibandronate (IBN) in hypogonadal CTX recipients. 52 male patients entered the study and received IBN (quarterly 2 μg i.v.). 60% of the pati...